Bromelain: A Review on its Potential as a Therapy for the Management of Covid-19

B V Owoyele1, A O Bakare2, M O Ologe3

  • 1Department of Physiology, University of Ilorin. deleyele@yahoo.com.

Insights

Bromelain shows potential for treating Coronavirus Disease 2019 (COVID-19) symptoms. Its anti-inflammatory and anticoagulatory properties may help manage severe illness progression.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Coronavirus Disease 2019 (COVID-19), caused by SARS-COV-2, is a severe global health crisis.
  • High mortality rates are linked to severe inflammation and systemic coagulation.
  • Existing treatments, including repurposed drugs, have shown limited success.

Purpose of the Study:

  • To review the potential therapeutic benefits of bromelain for COVID-19 symptoms.
  • To evaluate bromelain's anti-inflammatory and anticoagulatory properties in the context of COVID-19.

Main Methods:

  • Literature review of experimental and clinical evidence.
  • Analysis of bromelain's pharmacological effects.

Main Results:

  • Bromelain exhibits significant anti-inflammatory properties.
  • Bromelain demonstrates anticoagulatory effects.
  • Evidence suggests bromelain may inhibit or prevent COVID-19 symptoms.

Conclusions:

  • Bromelain is a promising candidate for managing COVID-19 symptoms.
  • Its properties may help slow disease progression and reduce complications.
  • Further clinical investigation into bromelain for COVID-19 is warranted.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
93
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.0K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
541
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
288
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
199
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
330